A multi-country cluster of multidrug-resistant tuberculosis (MDR TB) involving 28 migrants has been delineated by whole genome sequencing (WGS) in migrants recently having arrived from countries in the Horn of Africa. Although the number of cases detected so far is small, there is a possibility that more cases associated with this cluster may still be identified.
14 April 2017 | ECDC
Outside of a small number of clinical trials and compassionate use programmes, only 469 people received delamanid in 2016, while just over 4,300 received bedaquiline. All other people receiving DR-TB treatment continue instead to be treated with older, more toxic regimens that cure only 50 per cent of people treated, and cause severe side-effects, ranging from deafness to psychosis.
27 March 2017 | Médecins Sans Frontières (MSF) International
On World Tuberculosis Day, TB Alliance and the Medicines Patent Pool (MPP) announced a licensing agreement for the clinical development of sutezolid, an antibiotic drug candidate which demonstrated encouraging results in early studies. The sublicense pertains to the development of sutezolid in combination with other TB drugs and follows the MPP's license for the treatment signed with patent holder The Johns Hopkins University in January.
24 March 2017 | Yahoo Finance
New antibiotics that could treat tuberculosis may rapidly become ineffective, according to new research published by the Lancet ahead of World Tuberculosis Day. The rise in multi-drug resistant tuberculosis, which affected 480,000 people in 2015, could mean that even newly discovered drugs will soon be useless, the study found.
24 March 2017 | Inter Press Service
Rising rates of superbug tuberculosis (TB) are threatening to derail decades of progress against the contagious disease, experts said on Thursday, and new drugs powerful enough to treat them are few and far between.
23 March 2017 | Reuters
While the unveiling of a list highlighting the need to fund drug development against specific pathogens represented just a beginning for some antimicrobial resistance fighting efforts, the list represented a setback for TB drug development, advocates say.
02 March 2017 | Science Speaks
Taking a new approach toward tuberculosis therapy, a UCLA-led research team has devised a potential drug regimen that could cut the treatment time by up to 75 percent, while simultaneously reducing the risk that patients could develop drug-resistant TB.
26 January 2017 | UCLA
While deal marks a critical step in the fight against TB, health groups warn that the deal lacks safeguards that would ensure worldwide affordability.
26 January 2017 | MSF Access Campaign
The Medicines Patent Pool today announced that it has signed a licence with Johns Hopkins University to facilitate the clinical development of tuberculosis (TB) drug candidate sutezolid. The antibiotic sutezolid has long been considered a promising investigational treatment that, if further developed in combination with other drugs, could be used to more effectively treat both drug-sensitive and drug-resistant TB in patients.
25 January 2017 | Medicines Patent Pool
An 18-year-old woman and her family have won a battle in an Indian court to gain access to a restricted tuberculosis drug that her doctors say she needs to survive.
24 January 2017 | Wall Street Journal (blog)